Galectin Therapeutics, Inc., announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application “Method for Treatment of Pulmonary Fibrosis” — number 13/999,389 — on its lead compound GR-MD-02.
Galectin Therapeutics is currently developing carbohydrate-based therapies to treat fibrotic liver disease and cancer, and based on the workings of galectin proteins — key mediators of biologic function. This patent, when issued, will extend coverage of GR-MD-02, a proprietary polysaccharide pharmaceutical preparation that inhibits galectin proteins, to the treatment of patients at risk of pulmonary fibrosis (PF). The patent will cover a new treatment option of primary lung fibrosis, like idiopathic pulmonary fibrosis (IPF), and secondary lung fibrosis.
GR-MD-02 is currently being evaluated in several trials:
- A preclinical testing for lung, kidney and cardiovascular fibrosis;
- Two Providence Portland Medical Center clinical trials in melanoma patients, using the compound in combination with Keytruda and in combination with Yervoy;
- A Phase 2 trial in people with non-alcoholic steatohepatitis (NASH) with cirrhosis;
- A Phase 2 trial in subjects with NASH with advanced fibrosis; and
- A Phase 2a trial in patients with moderate to severe plaque psoriasis.